<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="10.3390/pathogens8040216pathogens-08-00216 : Article Assessment of Immunogenicity and Efficacy of a" exact="Zika" post="Vaccine Using Modified Vaccinia Ankara Virus as Carriers https://orcid.org/0000-0001-7932-2341López-CamachoCésar1†https://orcid.org/0000-0003-2847-9407KimYoung"/>
 <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Zika" post="virus (ZIKV) is an emerging mosquito-borne flavivirus that has"/>
 <result pre="stimulate effective immunity in mice and provide protection upon a" exact="ZIKV" post="challenge model, using a non-adjuvanted single vaccination approach. In"/>
 <result pre="constructed various modified vaccinia Ankara (MVA) viruses to express the" exact="ZIKV" post="Envelope (E) with modifications on the precursor membrane (prM)"/>
 <result pre="were evaluated as a non-adjuvanted single vaccination regimen against a" exact="ZIKV" post="Brazilian isolate, using viraemia as the correlate of protection."/>
 <result pre="by all MVA vectored vaccines and sub-optimal efficacy in a" exact="ZIKV" post="challenge model. Our results indicate the requirement of additional"/>
 <result pre="afford sterile protection upon a non-adjuvanted and single vaccination regime." exact="Zika" post="virus MVA envelope proteins vaccines immunogenicity efficacy mice 1."/>
 <result pre="virus MVA envelope proteins vaccines immunogenicity efficacy mice 1. Introduction" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus virus that belongs"/>
 <result pre="discovery in 1947 from a sentinel rhesus monkey in Uganda," exact="ZIKV" post="caused sporadic outbreaks in Africa and South Asia until"/>
 <result pre="in Micronesia in 2007 and French Polynesia in 2013 [2,3]." exact="ZIKV" post="has spread rapidly throughout the Americas since its first"/>
 <result pre="in 2015 [4], affecting more than 70 countries worldwide [5]." exact="ZIKV" post="is classified into two lineages: African (AF) and Asian"/>
 <result pre="outbreaks occurring worldwide. The main vector for urban transmission of" exact="ZIKV" post="is the Aedes mosquito, although sexual contact and vertical"/>
 <result pre="are also responsible for the virus dissemination [7]. Infection by" exact="ZIKV" post="is associated with neurological complications, such as microcephaly in"/>
 <result pre="licensed vaccines are yet available against ZIKV. There are many" exact="ZIKV" post="vaccine candidates, such as inactivated virus, based on DNA,"/>
 <result pre="vectors encoding the precursor membrane (prM) and the envelope (E)" exact="ZIKV" post="proteins, which are currently in phase I or II"/>
 <result pre="[12,13,14,15,16]. We have previously reported the development of four ChAdOx1" exact="ZIKV" post="vaccine candidates and their protective efficacy in a homologous"/>
 <result pre="ZIKV vaccine candidates and their protective efficacy in a homologous" exact="ZIKV" post="challenge model [17]. All four ChAdOx1 ZIKV vaccine candidates"/>
 <result pre="in a homologous ZIKV challenge model [17]. All four ChAdOx1" exact="ZIKV" post="vaccine candidates (prME, prME ΔTM, Env, and Env ΔTM)"/>
 <result pre="Env ΔTM) were shown to stimulate the production of anti-E" exact="ZIKV" post="antibodies and demonstrated protective efficacy in a homologous ZIKV-lineage"/>
 <result pre="transmembrane domain (prME ΔTM) induced the highest titres of anti-envelope" exact="ZIKV" post="antibodies that provided 100% efficacy against ZIKV infection, with"/>
 <result pre="titres of anti-envelope ZIKV antibodies that provided 100% efficacy against" exact="ZIKV" post="infection, with only a single and non-adjuvanted vaccination. Here,"/>
 <result pre="measured at 4 weeks and 12 weeks post-immunisation. In a" exact="ZIKV" post="mice challenge model, two MVA-ZIKV vaccine candidates (Env ΔTM"/>
 <result pre="in viral load in mice. This study reports that MVA" exact="ZIKV" post="vaccine candidates may be a limited candidate for further"/>
 <result pre="single-vaccination approach. 2. Results 2.1. Modified Vaccinia Ankara (MVA) Expressing" exact="ZIKV" post="Antigens To generate MVA-based ZIKV vaccine candidates, we sub-cloned"/>
 <result pre="Modified Vaccinia Ankara (MVA) Expressing ZIKV Antigens To generate MVA-based" exact="ZIKV" post="vaccine candidates, we sub-cloned each of the ZIKV transgenes"/>
 <result pre="generate MVA-based ZIKV vaccine candidates, we sub-cloned each of the" exact="ZIKV" post="transgenes (prME, prME ΔTM, Env, Env ΔTM) with parental"/>
 <result pre="as described elsewhere [18] (Figure 1c). The expression of the" exact="ZIKV" post="immunogens was confirmed by western blot in cells extracts"/>
 <result pre="showed that MVA viral vectors are correctly packaged, carrying the" exact="ZIKV" post="transgenes in their genome and more importantly, that they"/>
 <result pre="that they are capable of inducing the expression of the" exact="ZIKV" post="E in transduced cells. 2.2. Assessment of Immunogenicity We"/>
 <result pre="of cellular responses were detected at 4 weeks post-immunisation. 2.3." exact="ZIKV" post="Challenge in BALB/c Mice To assess the efficacy of"/>
 <result pre="at four-weeks post-immunisation (n = 5) were intravenously challenged with" exact="ZIKV" post="(strain Brazil ZKV2015; ZIKV-BR), as previously described [17]. Vaccine"/>
 <result pre="(qPCR); at 0, 1, 2, 3, 4, and 7-days post" exact="ZIKV" post="challenge (Figure 3). The naïve control group challenged with"/>
 <result pre="ZIKV challenge (Figure 3). The naïve control group challenged with" exact="ZIKV" post="displayed the expected viraemia kinetics, comprising a viral load"/>
 <result pre="a single dose of MVA-ZIKV vaccines conferred partial protection against" exact="ZIKV" post="challenge. For the MVA prME vaccinated group, all mice"/>
 <result pre="the rest of the MVA-ZIKV vaccines, by substantially reducing the" exact="ZIKV" post="loads in blood, such protection did not reach 100%"/>
 <result pre="protection in BALB/c mice challenged with ZIKV. 3. Discussion A" exact="ZIKV" post="vaccine target product profile [20] indicates that a preferred"/>
 <result pre="profile [20] indicates that a preferred dose regimen in a" exact="Zika" post="vaccine development is a single immunisation, although a minimal"/>
 <result pre="We have previously demonstrated that a non-replicative adenoviral-vectored vaccine expressing" exact="ZIKV" post="antigens induces high levels of immunity and protective efficacy"/>
 <result pre="induces high levels of immunity and protective efficacy in a" exact="ZIKV" post="mice challenge model against a ZIKV-BR strain, all upon"/>
 <result pre="Particles (VLPs) and inducing partial protection in mice after a" exact="ZIKV" post="challenge, upon a homologous prime-boost approach [21]. Of particular"/>
 <result pre="an MVA vaccine expressing the non-structural protein 1 (NS1) of" exact="ZIKV" post="has been demonstrated to be 100% effective in both"/>
 <result pre="a BALB/c mouse strain that had no lethal outcome upon" exact="ZIKV" post="infection. Hence, we measured vaccine efficacy by means of"/>
 <result pre="further studies, such as the use of a highly susceptible" exact="ZIKV" post="challenge model in A129, mice would be helpful to"/>
 <result pre="model in A129, mice would be helpful to explore the" exact="ZIKV" post="presence in key organs, such as the brain, spleen,"/>
 <result pre="of MVA-ZIKV vaccines in preventing viraemia, it is expected that" exact="ZIKV" post="viral loads may be found in those organs. Lastly,"/>
 <result pre="single immunisation in inbred and outbred mice, respectively [17]. Various" exact="ZIKV" post="vaccine platforms based on the ZIKV envelope have been"/>
 <result pre="mice, respectively [17]. Various ZIKV vaccine platforms based on the" exact="ZIKV" post="envelope have been reported, which consist of DNA, mRNA,"/>
 <result pre="and using different routes of administrations. Therefore, levels of immunogenicity," exact="ZIKV" post="neutralisation, or in vivo efficacy outcomes are still a"/>
 <result pre="development of an efficacious vaccine development that could prevent future" exact="ZIKV" post="outbreaks. 4. Materials and Methods Female inbred BALB/c mice"/>
 <result pre="BALB/c mice were used for the assessment of immunogenicity and" exact="ZIKV" post="challenge. Mice were purchased from either Envigo (Bicester, UK)"/>
 <result pre="Review Committee (P9804B4F1). Animal experiments performed at Harvard (immunisation and" exact="ZIKV" post="challenge) were approved by the BIDMC Institutional Animal Care"/>
 <result pre="plasmid was used as template to further generate the four" exact="ZIKV" post="antigens (prME, prME ΔTM, Env, and Env ∆TM) as"/>
 <result pre="prME ΔTM, Env, and Env ∆TM) as previously described ([17])." exact="ZIKV" post="antigens were used to generate MVA viruses as previously"/>
 <result pre="infected with MVA for homologous recombination and insertion of the" exact="ZIKV" post="ORF and GFP marker gene at a TK locus"/>
 <result pre="microscope (FEI, Eindhoven, The Netherlands). To test the expression of" exact="ZIKV" post="antigens, BHK-21 cells were transfected with rMVA. At 24"/>
 <result pre="incubated with 1:1000 anti-Zika Env monoclonal antibody (mouse mAb to" exact="Zika" post="Env protein, AZ1176, Aalto BioReagents, Dublin, Republic of Ireland)."/>
 <result pre="dose of new recombinant modified vaccinia ankara (MVA) encoding the" exact="ZIKV" post="antigens at a dose of 1 × 106 PFU."/>
 <result pre="(IM) and diluted in endotoxin-free PBS. Enzyme-linked immunosorbent assay (ELISA)-recombinant" exact="ZIKV" post="Envelope protein was used to measure anti-ZIKV envelope antibody"/>
 <result pre="[19]. Briefly, Nunc Maxisorp Immuno ELISA plates were coated with" exact="Zika" post="virus envelope antigen (Env-CD4) diluted in PBS to a"/>
 <result pre="after single immunisation with MVA-ZIKV vaccine. Mice sera reactive to" exact="ZIKV" post="E was serially diluted three-fold down in PBS/T with"/>
 <result pre="Spot forming cells (SFC)/106 PBMCs producing IFNγ were calculated. The" exact="ZIKV" post="challenge was performed as described [26]. Briefly, naïve and"/>
 <result pre="plaque-forming units (PFU)) of the ZIKV-BR strain. Viral loads following" exact="ZIKV" post="challenge were quantitated by RT-PCR at day 1, 2,"/>
 <result pre="in a blind experiment. After the experimental outcome of the" exact="ZIKV" post="challenge, samples were decoded. Viral loads were assessed as"/>
 <result pre="per mL. The infectivity of virus in peripheral blood from" exact="ZIKV" post="challenged mice was confirmed by PFU assays. Specific primers"/>
 <result pre="to amplify a region contained in the Capsid of the" exact="ZIKV" post="genome. Acknowledgments We would like to thank the Jenner"/>
 <result pre="and performed the animal experiments. P.A. and R.A.L. performed the" exact="ZIKV" post="challenge model and the RT-PCR viral loads. C.L.-C., Y.C.K.,"/>
 <result pre="C.L.-C., Y.C.K., P.A. and R.A.L. performed ELISA assays and analysed" exact="ZIKV" post="challenge data. Y.C.K. produced the ZIKV envelope protein. Y.C.K."/>
 <result pre="ELISA assays and analysed ZIKV challenge data. Y.C.K. produced the" exact="ZIKV" post="envelope protein. Y.C.K. performed ELISPOT, cell culture, transfections and"/>
 <result pre="Health (ODA), 16/107/05 (Design, development and GMP manufacture of a" exact="Zika" post="vaccine). Conflicts of Interest A.R.-S. and C.L.-C. are co-inventors"/>
 <result pre="Conflicts of Interest A.R.-S. and C.L.-C. are co-inventors of the" exact="Zika" post="vaccines described in this manuscript, filed by Oxford University"/>
 <result pre="University Innovation Limited in the International Patent Application No. PCR/GB2017/052220" exact="Zika" post="Vaccine. The remaining authors declare no competing interests. References"/>
 <result pre="https://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/(accessed on 25 July 2019) 6.FayeO.FayeO.DialloD.DialloM.WeidmannM.SallA.A.Quantitative real-time PCR detection of" exact="Zika" post="virus and evaluation with field-caught MosquitoesVirol. J.20131031110.1186/1743-422X-10-31124148652 7.PetersenL.R.JamiesonD.J.PowersA.M.HoneinM.A.Zika VirusN."/>
 <result pre="J.20131031110.1186/1743-422X-10-31124148652 7.PetersenL.R.JamiesonD.J.PowersA.M.HoneinM.A.Zika VirusN. Engl. J. Med.20163741552156310.1056/NEJMra160211327028561 8.CauchemezS.BesnardM.BompardP.DubT.Guillemette-ArturP.Eyrolle-GuignotD.SaljeH.Van KerkhoveM.D.AbadieV.GarelC.et al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013–2015: A retrospective"/>
 <result pre="MicrocephalyN. Engl. J. Med.201637495195810.1056/NEJMoa160065126862926 10.Cao-LormeauV.-M.BlakeA.MonsS.LastèreS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 11.DiamondM.S.LedgerwoodJ.E.PiersonT.C.Zika"/>
 <result pre="multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidatePLoS ONE20105e1398310.1371/journal.pone.001398321085591 17.López-CamachoC.AbbinkP.LaroccaR.A.DejnirattisaiW.BoydM.Badamchi-ZadehA.WallaceZ.R.DoigJ.VelazquezR.S.NetoR.D.L.et al.Rational" exact="Zika" post="vaccine design via the modulation of antigen membrane anchors"/>
 <result pre="Vaccinia Virus in Infected Human CellsJ. Virol.200377106061062210.1128/JVI.77.19.10606-10622.200312970445 19.KimY.C.Lopez-CamachoC.NettleshipJ.E.RahmanN.HillM.L.Silva-ReyesL.Ortiz-MartinezG.Figueroa-AguilarG.MarM.A.Vivanco-CidH.et al.Optimization of" exact="Zika" post="virus envelope protein production for ELISA and correlation of"/>
 <result pre="Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing" exact="Zika" post="Virus Structural Proteins Controls Zika Virus Replication in MiceSci."/>
 <result pre="Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls" exact="Zika" post="Virus Replication in MiceSci. Rep.201881738510.1038/s41598-018-35724-630478418 22.BraultA.C.DomiA.McDonaldE.M.Talmi-FrankD.McCurleyN.BasuR.RobinsonH.L.HellersteinM.DuggalN.K.BowenR.A.et al.A Zika Vaccine"/>
 <result pre="Proteins Controls Zika Virus Replication in MiceSci. Rep.201881738510.1038/s41598-018-35724-630478418 22.BraultA.C.DomiA.McDonaldE.M.Talmi-FrankD.McCurleyN.BasuR.RobinsonH.L.HellersteinM.DuggalN.K.BowenR.A.et al.A" exact="Zika" post="Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in"/>
 <result pre="cellular immune responses in miceVaccine2017353780378810.1016/j.vaccine.2017.05.03228579232 26.LaroccaR.A.AbbinkP.PeronJ.P.S.de ZanottoP.M.A.IampietroM.J.Badamchi-ZadehA.BoydM.Ng’ang’aD.KirilovaM.NityanandamR.et al.Vaccine protection against" exact="Zika" post="virus from BrazilNature201653647447810.1038/nature1895227355570 Figure 1 MVA-ZIKV vaccine designs. (a)"/>
 <result pre="cassette used to produce the recombinant MVA vectors, containing the" exact="ZIKV" post="structural genes shown in blue box. ((b), left panel)"/>
 <result pre="sequence (red box in Figure 1a) plus each of the" exact="ZIKV" post="transgenes. Asterisks denote the MVA backbone plasmid. ((b), right"/>
 <result pre="particles were detected [18]. Bar, 500 nm. (d) Expression of" exact="ZIKV" post="immunogens by western blot of BHK21 cell extracts transduced"/>
 <result pre="in size can be appreciated in the monomeric form of" exact="ZIKV" post="E (around 45 kDa for full length E, in"/>
 <result pre="were intramuscularly immunised with a single dose of MVA encoding" exact="ZIKV" post="antigens at 1 × 106 plaque forming units (PFU)/mouse."/>
 <result pre="immunisation were quantified by ELISA in plates coated with a" exact="ZIKV" post="E protein [19]. (c) Cellular immune responses to MVA-ZIKV"/>
 <result pre="by (IFNγ) ex vivo ELISPOT, and 20-mer peptides spanning the" exact="ZIKV" post="prME proteins at 10 μg/mL were used for stimulation."/>
 <result pre="PFU of ZIKV-BR strain, at four weeks post immunisation. After" exact="ZIKV" post="challenge, viral loads were monitored for seven days. (b)"/>
</results>
